Alternating R-CHOP and R-cytarabine is a safe and effective
regimen for transplant-ineligible patients with a newly
diagnosed mantle cell lymphoma

J 2018

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma

KLENER, Pavel, Eva FRONKOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK et. al.

Základní údaje

Originální název

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma

Autoři

KLENER, Pavel (203 Česká republika, garant), Eva FRONKOVA (203 Česká republika), David BELADA (203 Česká republika), Kristina FORSTEROVA (203 Česká republika), Robert PYTLIK (203 Česká republika), Marketa KALINOVA (203 Česká republika), Martin SIMKOVIC (203 Česká republika), David ŠÁLEK (203 Česká republika, domácí), Heidi MOCIKOVA (203 Česká republika), Vít PROCHAZKA (203 Česká republika), Petra BLAHOVCOVA, Andrea JANÍKOVÁ (203 Česká republika, domácí), Jana MARKOVA (203 Česká republika), Ales OBR (203 Česká republika), Adela BERKOVA (203 Česká republika), Jozef KUBINYI (203 Česká republika), Martina VASKOVA (203 Česká republika), Ester MEJSTRIKOVA (203 Česká republika), Vít CAMPR (203 Česká republika), Radek JAKSA (203 Česká republika), Roman KODET (203 Česká republika), Kyra MICHALOVA (203 Česká republika), Jan TRKA (203 Česká republika) a Marek TRNENY (203 Česká republika)

Vydání

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2018, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.439

Kód RIV

RIV/00216224:14110/18:00104075

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/hon.2483

UT WoS

000425633300016

Klíčová slova anglicky

elderly patients; high-dose cytarabine; mantle cell lymphoma; PET-CT; rituximab maintenance

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2019 20:18, Soňa Böhmová

Anotace

V originále

Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3+3cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70years. Most patients had intermediate (39.7%) and high-risk (50.7%) disease according to MCL international prognostic index. Rituximab maintenance was initiated in 58 patients. Overall response rate reached 89% by positron emission tomography-computed tomography, including 75.3% complete remissions. Two patients (2.7%) did not complete the induction therapy because of toxicity. Three patients (4.1%) were considered nonresponders, which led to therapy change before completion of induction. Estimated progression-free survival and overall survival were 51.3% and 68.6% at 4years, respectively. Mantle cell lymphoma international prognostic index, bulky disease ( 5cm), and achievement of positron emission tomography-negativity independently correlated with progression-free survival. Grade 3 to 4 hematologic and nonhematologic toxicity was documented in 48% and 20.5% patients, respectively. Alternation of R-CHOP and R-cytarabine represents feasible and very effective regimen for elderly/comorbid MCL patients. This study was registered at GovTrial () NCT03054883.

Citovat

KLENER, Pavel, Eva FRONKOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Marketa KALINOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vít PROCHAZKA, Petra BLAHOVCOVA, Andrea JANÍKOVÁ, Jana MARKOVA, Ales OBR, Adela BERKOVA, Jozef KUBINYI, Martina VASKOVA, Ester MEJSTRIKOVA, Vít CAMPR, Radek JAKSA, Roman KODET, Kyra MICHALOVA, Jan TRKA a Marek TRNENY. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2018, roč. 36, č. 1, s. 110-115. ISSN 0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2483.

@article{1450957,
   author = {Klener, Pavel and Fronkova, Eva and Belada, David and Forsterova, Kristina and Pytlik, Robert and Kalinova, Marketa and Simkovic, Martin and Šálek, David and Mocikova, Heidi and Prochazka, Vít and Blahovcova, Petra and Janíková, Andrea and Markova, Jana and Obr, Ales and Berkova, Adela and Kubinyi, Jozef and Vaskova, Martina and Mejstrikova, Ester and Campr, Vít and Jaksa, Radek and Kodet, Roman and Michalova, Kyra and Trka, Jan and Trneny, Marek},
   article_location = {MALDEN, USA},
   article_number = {1},
   doi = {http://dx.doi.org/10.1002/hon.2483},
   keywords = {elderly patients; high-dose cytarabine; mantle cell lymphoma; PET-CT; rituximab maintenance},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma},
   volume = {36},
   year = {2018}
}

TY  - JOUR
ID  - 1450957
AU  - Klener, Pavel - Fronkova, Eva - Belada, David - Forsterova, Kristina - Pytlik, Robert - Kalinova, Marketa - Simkovic, Martin - Šálek, David - Mocikova, Heidi - Prochazka, Vít - Blahovcova, Petra - Janíková, Andrea - Markova, Jana - Obr, Ales - Berkova, Adela - Kubinyi, Jozef - Vaskova, Martina - Mejstrikova, Ester - Campr, Vít - Jaksa, Radek - Kodet, Roman - Michalova, Kyra - Trka, Jan - Trneny, Marek
PY  - 2018
TI  - Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma
JF  - Hematological Oncology
VL  - 36
IS  - 1
SP  - 110-115
EP  - 110-115
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - elderly patients
KW  - high-dose cytarabine
KW  - mantle cell lymphoma
KW  - PET-CT
KW  - rituximab maintenance
N2  - Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3+3cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70years. Most patients had intermediate (39.7%) and high-risk (50.7%) disease according to MCL international prognostic index. Rituximab maintenance was initiated in 58 patients. Overall response rate reached 89% by positron emission tomography-computed tomography, including 75.3% complete remissions. Two patients (2.7%) did not complete the induction therapy because of toxicity. Three patients (4.1%) were considered nonresponders, which led to therapy change before completion of induction. Estimated progression-free survival and overall survival were 51.3% and 68.6% at 4years, respectively. Mantle cell lymphoma international prognostic index, bulky disease ( 5cm), and achievement of positron emission tomography-negativity independently correlated with progression-free survival. Grade 3 to 4 hematologic and nonhematologic toxicity was documented in 48% and 20.5% patients, respectively. Alternation of R-CHOP and R-cytarabine represents feasible and very effective regimen for elderly/comorbid MCL patients. This study was registered at GovTrial () NCT03054883.
ER  -

KLENER, Pavel, Eva FRONKOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Marketa KALINOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vít PROCHAZKA, Petra BLAHOVCOVA, Andrea JANÍKOVÁ, Jana MARKOVA, Ales OBR, Adela BERKOVA, Jozef KUBINYI, Martina VASKOVA, Ester MEJSTRIKOVA, Vít CAMPR, Radek JAKSA, Roman KODET, Kyra MICHALOVA, Jan TRKA a Marek TRNENY. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2018, roč.~36, č.~1, s.~110-115. ISSN~0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2483.

Podrobný výpis o publikaci